Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ABILIFY MYCITE KIT vs FIORINAL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Aripiprazole is a partial agonist at D2 and D3 dopamine receptors and 5-HT1A serotonin receptors, and an antagonist at 5-HT2A serotonin receptors. It also exhibits moderate affinity for histamine H1 receptors and alpha1-adrenergic receptors. The My Cite kit includes a sensor that detects tablet ingestion and transmits data to a wearable patch.
FIORINAL is a combination of butalbital (barbiturate), aspirin (NSAID), and caffeine. Butalbital potentiates GABA-A receptor activity, producing sedative-hypnotic effects. Aspirin inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, which provides analgesic and antipyretic effects. Caffeine is a non-selective adenosine receptor antagonist, enhancing analgesic efficacy.
Schizophrenia,Acute manic/mixed episodes associated with bipolar I disorder,Maintenance treatment of bipolar I disorder,Major depressive disorder (adjunctive therapy),Irritability associated with autistic disorder,Tourette's disorder
Relief of tension-type headache,Relief of migraine headache (off-label)
Oral: 10-15 mg once daily; dose range 5-30 mg/day; titrate based on response and tolerability. The MYCITE sensor is applied to the tablet; the patch and app are for adherence monitoring only.
1-2 capsules (butalbital 50 mg, acetaminophen 300 mg, caffeine 40 mg) orally every 4 hours as needed, not exceeding 6 capsules per day.
Aripiprazole: 75 hours (range 48–146 h). Dehydro-aripiprazole: 94 hours (range 48–206 h). Steady state reached in 14 days.
Butalbital 35-50 hours, aspirin 15-20 minutes (salicylate 2-3 hours at low doses, >20 hours at high doses), caffeine 3-5 hours. Prolonged in hepatic/renal impairment.
Aripiprazole is metabolized primarily by CYP2D6 and CYP3A4. The major active metabolite is dehydro-aripiprazole (formed by CYP2D6). Phase I reactions include dehydrogenation and hydroxylation. Phase II glucuronidation of hydroxylated metabolites occurs.
Butalbital is extensively metabolized in the liver via hydroxylation and glucuronidation, primarily by CYP2C9 and CYP2C19. Aspirin is hydrolyzed to salicylic acid, then conjugated with glycine (salicyluric acid) and glucuronidated. Caffeine is metabolized by CYP1A2 to paraxanthine, theobromine, and theophylline.
Aripiprazole: ~25% renal, ~55% fecal; unchanged drug accounts for <1% renal. Dehydro-aripiprazole (active metabolite): excreted similarly.
Renal: 60% butalbital (mostly unchanged), 10% aspirin (salicylates, majorly as metabolites), 3% caffeine (metabolites and unchanged). Fecal: <5% overall.
Aripiprazole: >99% bound to albumin and alpha-1-acid glycoprotein. Dehydro-aripiprazole: >99% bound.
Butalbital 20-40% (albumin), aspirin 80-90% (albumin, concentration-dependent), caffeine 25-36% (albumin).
Aripiprazole: 4.9 L/kg (IV). High Vd indicates extensive tissue distribution.
Butalbital 0.8 L/kg, aspirin 0.15-0.2 L/kg, caffeine 0.6-0.8 L/kg. Indicates extensive tissue distribution for butalbital and caffeine.
Oral: 87% (absolute). Tablet and orally disintegrating tablet are bioequivalent.
Oral: butalbital ~100%, aspirin 50-75% (first-pass metabolism), caffeine ~100%.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥15 m L/min). Not recommended for severe renal impairment (Cr Cl <15 m L/min) due to lack of data.
No specific guidelines; contraindicated in severe renal impairment (Cr Cl <30 m L/min) due to acetaminophen accumulation. Use with caution in moderate impairment.
Child-Pugh Class A or B: No dose adjustment necessary. Child-Pugh Class C: Use with caution; maximum dose 10 mg/day due to increased exposure.
Contraindicated in severe hepatic impairment (Child-Pugh Class C). For mild to moderate (Child-Pugh A or B), reduce dose by 50% or extend dosing interval.
Not approved for patients <18 years; safety and effectiveness not established.
Not recommended for pediatric use; safety and efficacy not established.
No specific dose adjustment; use lower starting doses (e.g., 5 mg/day) due to increased sensitivity and risk of adverse effects, especially orthostatic hypotension and tardive dyskinesia.
Start at lowest effective dose (e.g., 1 capsule every 4 hours) due to increased sensitivity to butalbital (sedation, confusion) and risk of acetaminophen hepatotoxicity; maximum daily acetaminophen dose 2 g.
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Aripiprazole is not approved for the treatment of patients with dementia-related psychosis.
None.
Neuroleptic malignant syndrome,Tardive dyskinesia,Metabolic changes including hyperglycemia/diabetes, dyslipidemia, weight gain,Orthostatic hypotension,Falls,Leukopenia/neutropenia/agranulocytosis,Seizures,Body temperature regulation impairment,Dysphagia,Suicidal thoughts/behaviors in adolescents/young adults with MDD
Risk of Reye's syndrome in children with viral illness,Aspirin hypersensitivity (e.g., asthma, nasal polyps),Gastrointestinal bleeding and ulceration,Hepatic impairment due to butalbital metabolism,Caffeine overdose from excessive use,Dependence and withdrawal with prolonged butalbital use
Hypersensitivity to aripiprazole or any component of the formulation,Concurrent use with ziprasidone (QT prolongation risk)
Hypersensitivity to butalbital, aspirin, or caffeine,Active peptic ulcer disease,Hemophilia or bleeding disorders,Concomitant use of anticoagulants,Children with chickenpox or influenza-like symptoms (risk of Reye's syndrome),Severe hepatic or renal impairment,Porphyria
No specific food interactions are reported for the sensor component. Aripiprazole can be taken with or without food. However, avoid excessive alcohol consumption as it may increase central nervous system depression or worsen side effects. Grapefruit and grapefruit juice do not significantly interact with aripiprazole metabolism (CYP3A4 minor pathway); no restriction needed.
Avoid excessive caffeine intake from coffee, tea, energy drinks, or chocolate as it may compound caffeine's stimulant effects and increase anxiety or insomnia. Alcohol should be strictly avoided due to additive CNS depression and increased GI bleeding risk with aspirin. No specific food restrictions besides moderation of caffeine-containing foods.
First trimester: Limited human data; animal studies show developmental toxicity (reduced fetal weight, delayed ossification) at doses similar to human exposure. Second/third trimester: Neonates exposed to antipsychotics (including aripiprazole) during late pregnancy may experience extrapyramidal symptoms and/or withdrawal symptoms (agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, feeding disorder).
First trimester: Butalbital is associated with neural tube defects, cleft palate; aspirin increases risk of gastroschisis, cardiac defects. Second trimester: Aspirin may cause premature closure of ductus arteriosus. Third trimester: Aspirin increases risk of intracranial hemorrhage, premature closure of ductus arteriosus; butalbital may cause neonatal withdrawal. Caffeine is not a major teratogen but high doses may increase miscarriage risk.
Aripiprazole is present in human breast milk; limited data suggest infant serum levels are low but can vary. M/P ratio not established. Caution advised; monitor infant for sedation, irritability, and feeding problems.
Aspirin excreted in milk (M/P ratio ~0.03-0.3); risk of Reye syndrome. Butalbital excreted in low amounts; may cause neonatal sedation. Caffeine excreted (M/P ~0.5-0.7); may cause irritability. Avoid breastfeeding during chronic use.
No specific dose adjustment recommended; however, pregnancy may alter aripiprazole pharmacokinetics (decreased exposure due to increased volume of distribution and clearance). Monitor clinical response and consider dose adjustment if efficacy or tolerability changes. Use lowest effective dose.
Due to increased renal clearance and volume of distribution, butalbital may require dose increase; aspirin may need higher doses due to increased plasma volume; no specific adjustment for caffeine. Monitor clinical response and toxicity.
Abilify My Cite is aripiprazole tablets embedded with an ingestible sensor (Ingestible Event Marker, IEM) that communicates with a wearable patch to record medication ingestion. It is used for schizophrenia, bipolar I disorder, and as adjunctive therapy for major depressive disorder. The sensor does not monitor drug levels or efficacy; it only confirms ingestion. Ensure the patient has a compatible smartphone and the My Cite app. The patch must be replaced weekly. Avoid MRI, CT, or diathermy near the patch; remove if undergoing these procedures. Monitor for aripiprazole side effects: akathisia, metabolic changes, tardive dyskinesia, and neuroleptic malignant syndrome. The ingestible sensor contains copper, magnesium, and silicon; allergy risk is low but possible.
FIORINAL (butalbital/aspirin/caffeine) is a barbiturate-containing combination analgesic. Due to butalbital's high abuse potential and risk of withdrawal, it is reserved for tension-type headaches refractory to non-barbiturate therapies. Monitor for signs of barbiturate dependence, and limit quantity dispensed. Avoid in patients with porphyria, severe hepatic impairment, or hemorrhagic disorders (aspirin component). Caffeine may exacerbate anxiety or insomnia.
Take Abilify My Cite by mouth as directed. The sensor in the tablet activates upon contact with stomach fluid. Wear the My Cite patch on your left upper abdomen, replacing it weekly. Use the My Cite app to scan the tablet's QR code and confirm ingestion. Do not crush or chew the tablet. If a dose is missed, take it as soon as remembered unless it is close to the next dose. Do not double doses.,The patch is not MRI compatible; remove it before any MRI, CT scan, or diathermy procedure. Inform all healthcare providers that you use this system. The patch contains no latex. You may feel a mild sensation when the patch communicates with your phone. Keep your phone nearby (within Bluetooth range) for recording.,Common side effects of aripiprazole include nausea, vomiting, constipation, headache, dizziness, insomnia, restlessness, and weight gain. Seek medical attention for severe muscle stiffness, fever, confusion, irregular heartbeat, or suicidal thoughts. Avoid alcohol and activities requiring mental alertness until you know how this medication affects you.,The ingestible sensor is generally safe, but if you have a sensitivity to copper, magnesium, or silicon, discuss with your doctor. The patch may cause skin irritation; if it persists, stop use and contact your provider.,Do not rely solely on the app to confirm ingestion; it is not a substitute for clinical judgment. Store tablets at room temperature, away from moisture and heat. Keep out of reach of children.
This medication contains butalbital, which can be habit-forming; do not exceed prescribed dose or duration.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, opioids) as they increase sedation and respiratory depression risk.,Do not drive or operate heavy machinery until you know how this drug affects you.,Take with food to reduce stomach upset; if you experience black or bloody stools, stop and seek immediate medical attention (signs of GI bleeding from aspirin).,Do not use more than directed; sudden discontinuation can cause withdrawal symptoms (anxiety, tremors, seizures).,Keep out of reach of children; overdose may be fatal.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ABILIFY MYCITE KIT vs FIORINAL, answered by our medical review team.
ABILIFY MYCITE KIT is a Atypical antipsychotic that works by Aripiprazole is a partial agonist at D2 and D3 dopamine receptors and 5-HT1A serotonin receptors, and an antagonist at 5-HT2A serotonin receptors. It also exhibits moderate affinity for histamine H1 receptors and alpha1-adrenergic receptors. The My Cite kit includes a sensor that detects tablet ingestion and transmits data to a wearable patch.. FIORINAL is a Barbiturate Analgesic Combination that works by FIORINAL is a combination of butalbital (barbiturate), aspirin (NSAID), and caffeine. Butalbital potentiates GABA-A receptor activity, producing sedative-hypnotic effects. Aspirin inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, which provides analgesic and antipyretic effects. Caffeine is a non-selective adenosine receptor antagonist, enhancing analgesic efficacy.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ABILIFY MYCITE KIT and FIORINAL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ABILIFY MYCITE KIT is: Oral: 10-15 mg once daily; dose range 5-30 mg/day; titrate based on response and tolerability. The MYCITE sensor is applied to the tablet; the patch and app are for adherence monitoring only.. The standard adult dose of FIORINAL is: 1-2 capsules (butalbital 50 mg, acetaminophen 300 mg, caffeine 40 mg) orally every 4 hours as needed, not exceeding 6 capsules per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ABILIFY MYCITE KIT and FIORINAL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ABILIFY MYCITE KIT is classified as Category C. First trimester: Limited human data; animal studies show developmental toxicity (reduced fetal weight, delayed ossification) at doses similar to human exposure. Second/third trimes. FIORINAL is classified as Category C. First trimester: Butalbital is associated with neural tube defects, cleft palate; aspirin increases risk of gastroschisis, cardiac defects. Second trimester: Aspirin may cause prem. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.